Overcoming Prescribing Inertia to Outperform Competitors
We were tasked with helping a global pharmaceutical company launch a new biologic in a market with deeply entrenched HCP prescribing habits. We needed to shift clinician decision-making to ensure a successful launch and better outcomes for patients.
Unlocking UK Adoption of a Type 2 Diabetes Therapy
We needed to help a client adapt a global messaging strategy for a breakthrough Type 2 diabetes therapy to unlock its adoption in the UK. Given the unique nature of treating diabetes in the UK, with its focus on primary care, the global messaging needed fine-tuning to reflect local HCP behaviours and context.
Exceeding US launch targets in Atopic Dermatitis
In a crowded atopic dermatitis market, our client launched a new biologic drug that, despite strong clinical data, risked being overlooked by clinicians due to prescribing inertia.
